51 results
6-K
EX-10.1
NLSP
NLS Pharmaceutics Ltd
21 Mar 24
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
5:14pm
the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser … and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
6-K
EX-4.2
NLSP
NLS Pharmaceutics Ltd
21 Mar 24
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
5:14pm
that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed
6-K
EX-4.1
NLSP
NLS Pharmaceutics Ltd
21 Mar 24
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
5:14pm
and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
6 Dec 23
Unaudited Interim Condensed Financial Statements
4:44pm
of commercialization in the U.S. and in the EU. The Company will be the sole party responsible for the design and execution of the research and development plan
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
1 Dec 23
Report of Foreign Private Issuer
7:35am
party responsible for the design and execution of the research and development plan, for the conduct and management of the preclinical as well
UPLOAD
fvgdce crpq5o1st
13 Dec 22
Letter from SEC
12:00am
6-K
EX-99.1
e8cinr 14
8 Dec 22
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.2
l8h959c
8 Dec 22
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.3
3ozx95 7j
8 Dec 22
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.2
9br2i70gckobkt2
3 Oct 22
Report of Foreign Private Issuer
8:51am
6-K
EX-99.1
bffisb
3 Oct 22
Report of Foreign Private Issuer
8:51am
6-K
EX-99.1
1vup1vyh
23 Aug 22
Report of Foreign Private Issuer
4:21pm
UPLOAD
vivl 0dno85abitlr6
16 Jun 22
Letter from SEC
12:00am
6-K
EX-10.1
g70 yehpddvsrarq
14 Apr 22
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:58pm
6-K
EX-10.2
02ptd xsfeabkmi
14 Apr 22
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:58pm
6-K
EX-4.2
6f2ezueyz54re cb0
14 Apr 22
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:58pm
6-K
EX-4.1
t9p9p2s8cwr9
14 Apr 22
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:58pm